GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Effective Interest Rate on Debt %

KRON (Kronos Bio) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Kronos Bio's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was $0.00 Mil. Kronos Bio's average total debt for the quarter that ended in Dec. 2024 was $25.35 Mil. Therefore, Kronos Bio's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 0.00%.


Kronos Bio Effective Interest Rate on Debt % Historical Data

The historical data trend for Kronos Bio's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Effective Interest Rate on Debt % Chart

Kronos Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 23.87 - - - -

Kronos Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kronos Bio's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Kronos Bio's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kronos Bio's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Effective Interest Rate on Debt % falls into.


;
;

Kronos Bio Effective Interest Rate on Debt % Calculation

Kronos Bio's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  0/( (28.272+24.9)/ 2 )
=-1  *  0/26.586
=0.00 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=25.379 + 2.893
=28.272

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=21.506 + 3.394
=24.9

Kronos Bio's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2024 )+Total Debt  (Q: Dec. 2024 ))/ count )
=-1  *  0/( (25.798+24.9)/ 2 )
=-1  *  0/25.349
=0.00 %

where

Total Debt  (Q: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.539 + 3.259
=25.798

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=21.506 + 3.394
=24.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Kronos Bio  (NAS:KRON) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Kronos Bio Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kronos Bio Business Description

Industry
Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 400, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Executives
Norbert W Bischofberger director, 10 percent owner, officer: President & CEO 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Jorge Dimartino officer: Chief Medical Officer & VP C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore officer: Chief Scientific Officer C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz officer: COO & General Counsel 3175 HANOVER STREET, PALO ALTO CA 94304
Sandra A. Gardiner officer: Interim CFO CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130